Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer.

[1]  Sanjay G. Patel,et al.  Trends in the use of perioperative chemotherapy for localized and locally advanced muscle-invasive bladder cancer: a sign of changing tides. , 2015, European urology.

[2]  F. Montorsi,et al.  The effect of neoadjuvant chemotherapy on perioperative outcomes in patients who have bladder cancer treated with radical cystectomy: a population-based study. , 2014, European urology.

[3]  E. Wallen,et al.  Neoadjuvant chemotherapy for bladder cancer does not increase risk of perioperative morbidity , 2014, BJU international.

[4]  Y. Tomita,et al.  Randomised phase III study of neoadjuvant chemotherapy with methotrexate, doxorubicin, vinblastine and cisplatin followed by radical cystectomy compared with radical cystectomy alone for muscle-invasive bladder cancer: Japan Clinical Oncology Group Study JCOG0209. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  J. Witjes,et al.  EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. , 2014, European urology.

[6]  S. Barni,et al.  Correlation of pathologic complete response with survival after neoadjuvant chemotherapy in bladder cancer treated with cystectomy: a meta-analysis. , 2014, European urology.

[7]  J. Mackey,et al.  Expression of nucleoside transporters and deoxycytidine kinase proteins in muscle invasive urothelial carcinoma of the bladder: correlation with pathological response to neoadjuvant platinum/gemcitabine combination chemotherapy. , 2014, The Journal of urology.

[8]  P. Black,et al.  Re: Günter Niegisch, Anja Lorch, Michael J. Droller, Hugh J. Lavery, Kristian D. Stensland, Peter Albers. Neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: which patients benefit? Eur Urol 2013;64:355-7. , 2014, European urology.

[9]  Sanjay G. Patel,et al.  Trends in the utilization of neoadjuvant chemotherapy in muscle-invasive bladder cancer: results from the National Cancer Database. , 2014, Urology.

[10]  T. Dorff,et al.  Neoadjuvant chemotherapy with gemcitabine/cisplatin vs. methotrexate/vinblastine/doxorubicin/cisplatin for muscle-invasive urothelial carcinoma of the bladder: a retrospective analysis from the University of Southern California. , 2013, Urologic oncology.

[11]  A. Tafreshi,et al.  USANZ: Time‐trends in use and impact on outcomes of perioperative chemotherapy in patients treated with radical cystectomy for urothelial bladder cancer , 2013, BJU international.

[12]  P. Albers,et al.  Neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: which patients benefit? , 2013, European urology.

[13]  David C. Smith,et al.  A phase II trial of neoadjuvant nab-paclitaxel, carboplatin, and gemcitabine (ACaG) in patients with locally advanced carcinoma of the bladder. , 2013, Urology.

[14]  N. Vogelzang,et al.  Pooled analysis of clinical outcomes with neoadjuvant cisplatin and gemcitabine chemotherapy for muscle invasive bladder cancer. , 2013, The Journal of urology.

[15]  A. Zietman,et al.  Use of potentially curative therapies for muscle-invasive bladder cancer in the United States: results from the National Cancer Data Base. , 2013, European urology.

[16]  H. G. van der Poel,et al.  Response to induction chemotherapy and surgery in non-organ confined bladder cancer: a single institution experience. , 2013, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[17]  R. Takata,et al.  Neoadjuvant gemcitabine plus carboplatin for locally advanced bladder cancer. , 2013, Japanese journal of clinical oncology.

[18]  S. Pal,et al.  Retrospective analysis of clinical outcomes with neoadjuvant cisplatin-based regimens for muscle-invasive bladder cancer. , 2012, Clinical genitourinary cancer.

[19]  A. Bergman,et al.  Carboplatin based induction chemotherapy for nonorgan confined bladder cancer--a reasonable alternative for cisplatin unfit patients? , 2012, The Journal of urology.

[20]  R. Wahlqvist,et al.  Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer. , 2012, European urology.

[21]  A. Roychoudhury,et al.  Relative efficacy of perioperative gemcitabine and cisplatin versus methotrexate, vinblastine, adriamycin, and cisplatin in the management of locally advanced urothelial carcinoma of the bladder. , 2012, Urology.

[22]  A. Bossi.  Re: Arnulf Stenzl, Nigel C. Cowan, Maria De Santis, et al. Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU Guidelines. Eur Urol 2011;59:1009-18. , 2011, European urology.

[23]  E. Kikuchi,et al.  Neoadjuvant gemcitabine plus cisplatin for muscle-invasive bladder cancer. , 2011, Japanese journal of clinical oncology.

[24]  J. Witjes,et al.  Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. , 2011, European urology.

[25]  S. Ramsey,et al.  Patterns of use of systemic chemotherapy for Medicare beneficiaries with urothelial bladder cancer. , 2011, Urologic oncology.

[26]  A. Kibel.  International Phase III Trial Assessing Neoadjuvant Cisplatin, Methotrexate, and Vinblastine Chemotherapy for Muscle-Invasive Bladder Cancer: Long-Term Results of the BA06 30894 Trial , 2011 .

[27]  H. Grossman,et al.  Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy , 2009, Cancer.

[28]  David C. Smith,et al.  A sequential treatment approach to myoinvasive urothelial cancer: a phase II Southwest Oncology Group trial (S0219). , 2009, The Journal of urology.

[29]  H. Grossman,et al.  Commentary on A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: A retrospective experience , 2009 .

[30]  E. Klein,et al.  Lack of pathologic down‐staging with neoadjuvant chemotherapy for muscle‐invasive urothelial carcinoma of the bladder , 2009, Cancer.

[31]  David C. Smith,et al.  Phase II trial of paclitaxel, carboplatin and gemcitabine in patients with locally advanced carcinoma of the bladder. , 2008, The Journal of urology.

[32]  R. Dienstmann,et al.  Phase II trial of neoadjuvant gemcitabine and cisplatin in patients with resectable bladder carcinoma. , 2007, International braz j urol : official journal of the Brazilian Society of Urology.

[33]  Sergio Ricci,et al.  Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  C. Vale.  Neoadjuvant Chemotherapy in Invasive Bladder Cancer: Update of a Systematic Review and Meta-Analysis of Individual Patient Data: Advanced Bladder Cancer (ABC) Meta-analysis Collaboration , 2005 .

[35]  S. Ricci,et al.  Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder Cancer , 2005 .

[36]  Nicholas J Vogelzang,et al.  Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. , 2003, The New England journal of medicine.

[37]  C. Vale.  Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis , 2003, The Lancet.

[38]  A. Ribas,et al.  Carboplatin‐based versus cisplatin‐based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma , 1997, Cancer.

[39]  P. Rigatti,et al.  Neoadjuvant CMV Chemotherapy plus Radical Cystectomy in Locally Advanced Bladder Cancer: The Impact of Pathologic Response on Long-Term Results , 1996, Tumori.

[40]  H. Scher,et al.  Neoadjuvant chemotherapy and partial cystectomy for invasive bladder cancer. , 1994, Cancer treatment and research.